Evidence map›Paper›PMID 37063898›Full record

ArticleFrontiers in immunology2023

Etiology of end-stage liver cirrhosis impacts hepatic natural killer cell heterogenicity.

Ana C Maretti-Mira, Matthew P Salomon, Angela M Hsu, Lily Dara, Lucy Golden-Mason

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ana C Maretti-MiraUSC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Matthew P SalomonUSC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Angela M HsuUSC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Lily DaraUSC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
Lucy Golden-MasonUSC Research Center for Liver Disease, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
University of Southern California · US

Funding

USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOLDEN, LUCY MARY · 1995 to 2020
$21.8M
Human Group 2 Innate Lympohocyte Cell (ILC2) populations contribute to Hepatic FibrosisR01DK106491 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOLDEN, LUCY MARY · 2015 to 2019
$1.8M
Innate Immunity, Cholesterol, and NASH PathogenesisR01DK117004 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOLDEN, LUCY MARY · 2020 to 2023
$1.5M
NIDDK NIH HHS P30 DK048522NIDDK NIH HHS R01 DK106491NIDDK NIH HHS R01 DK117004
6 · The paper itself

Abstract

The natural killer (NK) cell population is a critical component of the innate immune compartment of the liver, and its functions are deeply affected by the surrounding environment. In the late stage of fibrosis, NK cells become dysfunctional, but the influence of disease etiology on NK cell behavior during cirrhosis remains unclear. Using single-cell RNA sequencing (scRNA-seq), we characterized the hepatic NK cells from end-stage cirrhotic livers from subjects with non-alcoholic steatohepatitis (NASH), chronic hepatitis C infection (HCV) and primary sclerosing cholangitis (PSC). Here, we show that although NK cells shared similar dysfunctions, the disease etiology impacts hepatic NK cell heterogeneity. Therapeutical strategies targeting NK cells for the prevention or treatment of fibrosis should consider liver disease etiology in their design.

Indexed as

Hepatitis C, ChronicLiver CirrhosisFibrosisHumansKiller Cells, NaturalcirrhosisHCVinnate lymphocyte cellsliverNASHnatural killer cellsPSCScRNA-seq

Identifiers

PMID37063898
PMCPMC10098346
OpenAlexW4361279139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.